One important step in developing online customer experiences is making sure that all customers – including those with disabilities – can experience them.
Leaked documents from provincial and municipal governments in China reveal a slew of previously unreported severe adverse events related to Covid-19 vaccines made and administered in China.
bluebird bio Presents New Results from Clinical Development Program of eli-cel Gene Therapy for CALD
Biologics License Application (BLA), Cerebral Adrenoleukodystrophy (CALD), Clinical Trial Endpoints, Clinical Trials, Committee for Medicinal Products for Human Use (CHMP), Data, Efficacy, European Medicines Agency (EMA), Gene Therapy, Major Functional Disabilities (MFDs), Marketing Authorization Application (MAA), Neurological function, R&D, Rare Metabolic Disordersbluebird bio Inc. announced updated results from the clinical development program for the company’s investigational elivaldogene autotemcel (eli-cel, Lenti-D) gene therapy in patients with cerebral adrenoleukodystrophy (CALD), including long-term results from the Phase 2/3 Starbeam study and data from the Phase 3 ALD-104 study.
This webinar will share key advocacy lessons about how to write persuasively, how to present public testimony and where to find key resources on jobs for people with disabilities.